Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome
← catalyst calendarSponsored by Quoin Pharmaceuticals (industry) · QNRX — their whole pipeline →.
Phase
Phase 2/3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
30estimated
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-06-23 | actual | When the study began enrolling |
| Primary completion | 2025-12-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2022-08-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Netherton Syndrome
Interventions
- Drug: QRX003-2% Lotion
- Drug: QRX003-4% Lotion QAM
- Drug: Vehicle
- Drug: QRX003-4% Lotion BID
Primary outcomes
what the primary-completion date above is the date OFEfficacy Endpoints-1-point IGA
measured Up to week 16
Efficacy Endpoints-2-point IGA
measured Up to week 16
Efficacy Endpoints-NS Sign
measured Up to week 16
Efficacy Endpoints-BSA
measured Up to week 16
Efficacy Endpoints-WI-NRS score
measured Up to week 16
Efficacy Endpoints-TSQM
measured Up to week 16
Efficacy Endpoints-Rescue Therapy
measured Up to week 16
Safety Endpoints-AEs
measured Up to week 16
Safety Endpoints-LSR
measured Up to week 16
Permalink · QNRX's whole pipeline · Catalyst calendar · Every registered study · What changed